Trial Profile
Phase II Trial of Palbociclib With Fulvestrant in Individuals With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Who Have Progressed on Treatment With Palbociclib and an Aromatase Inhibitor
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Palbociclib (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Pharmacodynamics; Therapeutic Use
- 01 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jul 2024.
- 03 Aug 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 03 Aug 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jan 2024.